Khiron has begun the integration of prescriptions covered by insurance in Colombia

TORONTO, Jan. 19, 2023 /CNW/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), it has been announced that medical drugs have started to be given to patients in Zerenia.TM hospital, under the insurance system approved by the Government of Colombia up January 1St2023.

Khiron Life Sciences Corp. logo (CNW Group/Khiron Life Sciences Corp.)

ZereniaTM is a health network of specialty clinics focused on treating chronic pain, neurological conditions, mental health, and sleep disorders. This is the most popular cannabis clinic network in the world Colombia, as evidenced by its recent contract with the Colombian public insurance company. In 2022, i Colombia Alone, the network hospital exceeded 130,000 individual consultations, up 20% from 2021, and has the physical capacity to reach over 300,000 interviews a year. In the first half of 2022, more than 40% of all consultations resulted in a prescription of cannabis. ZereniaTM there are places inside ColombiaBritain, Braziland Peru.

Alvaro TorresChief Executive of Khiron, said: “Thank you for the wise decision from the Government of Colombia including prescriptions of medical cannabis, many patients are leaving our hospitals and investing in life-changing medications. It’s great to see that pharmaceuticals are now an integral part of the patient’s journey to improve their lives. Our Zerenia hospitals are recognized nationwide by patients, doctors, insurance companies, and the Government, for our unique healthcare model and will continues to lead to the disruption of internal medicine. Colombia and outside.”

About Khiron Life Sciences Corp.

Khiron is a leading global pharmaceutical company with its core operations in-house Latin America and Europe. Using specialized healthcare facilities and telemedicine platforms, Khiron has combined a disease model, physician training programs, scientific expertise, product innovation, and focused on creating opportunities to take data and brand loyalty with patients to the whole world. The company has an internal sales force Colombia, Dutchof the United Kingdom, Switzerland, Peruand Brazil. The Company is led by its founder and Chief Executive Officer, Alvaro Torreswith a dedicated and diverse management team and board of directors.

Visit Khiron online at https://investors.khiron.ca.

Linkedin https://www.linkedin.com/company/khiron-life-sciences-corp/

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of applicable securities laws. All information contained herein is not historical in nature and includes forward-looking statements. The forward-looking statements contained in this news release may include statements regarding the expected results of operations and benefits for the Company from acquiring Target as well as information on business plans. The forward-looking statements and information contained in this news release reflect management’s current beliefs and are based on current information. available now and on the basis of opinions that management believes to be appropriate. These considerations include, but are not limited to, the expected benefits to Khiron’s business as a result of the acquisition of Target, and considerations regarding market opportunities in the jurisdictions in which the Company operates and where trying to make it work.

Although management believes its expectations and assumptions are reasonable, forward-looking statements are always subject to known and unknown risks, uncertainties, and other factors, many of which cannot be controlled by the management, may cause the difference of actual results from the material. those expressed or implied in such forward-looking statements. Such risks and uncertainties include but are not limited to the following: general economic conditions, adverse conditions in the stock market, political uncertainty, contingencies, failure to obtain regulatory requirements and approvals. , the inability to maintain required permits and licenses, business combination risks, as well as other risks discussed in Khiron’s most recent annual report form which found in Khiron’s SEDAR information at www.sedar.com.

As a result of the foregoing and other risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking statements. in this press release. Readers are further cautioned that the aforementioned risks and uncertainties are not exhaustive, and that there may be other risks and uncertainties, which are not known to the Company’s management, that may exist. cause actual results to differ from those expressed or implied in the forward-looking statements. in this press release. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Khiron disclaims any intention to update or revise any information presented herein, or as a result new information, future events or otherwise, unless required by law.

NEITHER THE TSX VENTURE EXCHANGE, NOR ITS TERMS OF USE OF THE SERVICE (EXCEPT AS REFERRED TO IN THE TSX VENTURE EXCHANGE’S TERMS OF USE), ACCEPT NO RESPONSIBILITY FOR THE ACCURACY OR ACCURACY OF THIS SITE.

Cision

Cision

See the first download ads:https://www.prnewswire.com/news-releases/khiron-begins-dispensation-of-insurance-covered-prescriptions-in-colombia-301725811.html

SOURCE Khiron Life Sciences Corp.

Cision

Cision

See the first download ads: http://www.newswire.ca/en/releases/archive/January2023/19/c3829.html

Leave a Comment